Royalty Pharma to Announce Third-Quarter 2020 Financial Results on November 11, 2020

Rhea-AI Summary

Royalty Pharma (Nasdaq: RPRX) plans to report its third quarter 2020 financial results on November 11, 2020, prior to the U.S. market opening. A conference call will be held at 8:00 a.m. ET that day, accessible via phone at (833) 519-1253 or (914) 800-3826 for international callers, using passcode 8067315. The live webcast will be available on the company’s Investors page. Royalty Pharma is recognized as the largest buyer of biopharmaceutical royalties and a key innovator in the biopharmaceutical sector.

Positive

• Scheduled reporting of Q3 earnings indicates transparency and commitment to shareholder communication.
• Royalty Pharma is the largest buyer of biopharmaceutical royalties, suggesting a strong market position.

Negative

• None.

NEW YORK, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced that it will report its third quarter 2020 financial results on Wednesday, November 11, 2020 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Conference Call Information

The conference call can be accessed live over the phone by dialling (833) 519-1253, or for international callers by dialling (914) 800-3826. The passcode to access the conference call is 8067315.

A live webcast may be accessed from the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and three development-stage product candidates.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-2295
ir@royaltypharma.com 

FAQ

When will Royalty Pharma report its Q3 2020 financial results?

Royalty Pharma will report its Q3 2020 financial results on November 11, 2020.

What time is the Royalty Pharma conference call for Q3 results?

The conference call will take place at 8:00 a.m. Eastern Time on November 11, 2020.

How can I access the Royalty Pharma conference call?

The conference call can be accessed by dialing (833) 519-1253 for U.S. callers or (914) 800-3826 for international callers.

What is the passcode for the Royalty Pharma conference call?

The passcode to access the conference call is 8067315.

Where can I find the webcast of the Royalty Pharma conference?

The live webcast can be accessed from the Investors page on Royalty Pharma's website.